Human induced pluripotent stem cells (hiPSCs) have the potential to revolutionize biomedical sciences, however the standardised mass production, indispensable for their industrial and therapeutic use, is still a major challenge. Impeller stirred-tank bioreactors, currently used for hiPSC bioprocessing, impose detrimental stresses on cultured hiPSCs, resulting in heterogeneity of cells and cell-agg ...